This article is more than 5 years old. Information may no longer be current.

Immune suppressant helps control refractory uveitis, study finds

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The immunosuppressant mycophenolate mofetil appears to be effective as an adjunctive treatment for refractory uveitis, according to a study.

Chun Lau and colleagues published a retrospective, open-label study of 14 patients with refractory panuveitis or posterior uveitis who were treated with CellCept (mycophenolate mofetil, Roche). Average treatment time was more than 33 months. Patients had uncontrolled inflammation despite high prednisolone maintenance dosage or other therapies.

Intraocular inflammation remained under control in 10 patients, was unchanged in three and deteriorated in one. Vision was improved in seven eyes (25%), unchanged in 14 eyes (50%) and reduced in the remaining seven eyes.

The study is published in Clinical and Experimental Ophthalmology.